CRP and hepatocellular carcinoma: Both CRP (0.8 μg/ml)-treated platelets and their releasate reduced the expression of KLF6 in HCC cells at the 12 and 24 hour time points, and these effects could be blocked by SB431542 (10 μM) (Fig. 5A and B).